Loop IleostomyPhase 2/3PHaLIRNCT03720262
Prevention of Hernia After Loop Ileostomy Reversal
A Phase 2/3 study testing Mesh reinforcement and No reinforcement in people with Loop Ileostomy, run by Karolinska Institutet at 4 sites in Sweden.
Trial summary
PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery are randomized between retro muscular mesh Ultrapro Advanced or standard treatment without mesh. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Loop Ileostomy
- What is being tested?
- Mesh reinforcement and No reinforcement
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 208 participants
- Where
- 4 sitesSweden
- Study dates
- 1 Mar 2018to 31 Dec 2029
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients operated for low anterior resection for rectal cancer with a diverting loop ileostomy and planned for stoma reversal
Who cannot join
- Language barrier or cognitive disability
- Recurrent cancer
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Jonas Nygren, MD, PhD contact
Sweden4 sites, 4 recruiting
- Recruiting
Södertälje Hospital
Södertälje
Sven Bringman
- Recruiting
Stockholm South General Hospital
Stockholm, 11883
Karolina Eklöf, MD
- Recruiting
Ersta Hospital
Stockholm
Jonas Nygren, MD, PhD
- Recruiting
Västmanland Hospital
Västerås
Abbas Chabok, MD PhD
About this study
PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery are randomized between retro muscular mesh Ultrapro Advanced or standard treatment without mesh.
Read the detailed description
A temporary loop ileostomy is widely used when operating rectal cancer. The ostomy is then reversed in a separate operation. Morbidity of stoma reversal is significant, but not clearly defined. One complication in connection with stoma closure is development of hernia at the former stoma site.
A hernia is a weakening of the muscular layers and the connective tissue of the abdominal wall, which may cause pain and discomfort, as well as an inconvenient bulge. A hernia could also cause more serious complication of obstructed or strangulated bowel. According to international studies, the incidence of hernia at the ostomy site varies between 7% and 35%. Many of the studies are heterogenic and some of them include both colostomies and ileostomies. Among studies that focus on reversal of ileotomies the hernia incidence varies between 11-15%. Preliminary results from a retrospective study in Stockholm indicates a frequency of 7,9%.
The best method to avoid hernia after stoma closure is not known. Most commonly surgeons tend to close the fascia in one layer with monofilament suture. In the study mentioned above 91% of the operations were done with one-layer monofilament, mostly PDS. Use of prophylactic mesh in the abdominal wall has been proposed, but there is currently insufficient scientific evidence to recommend it as a routine.
The present study is focused on loop ileostomy closure after rectal cancer. A non-heterogenous group of ostomies will serve as a base to evaluate whether the incidence of hernia may be reduced. If this study detects a decreased frequency of hernia when using prophylactic meshes, it may lead to new recommendations for this patient group.
PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery will be randomized to retro muscular mesh Ultrapro Advanced or standard treatment without mesh. Operating time, complications, LOS, pain, infections and postoperative hernia are to be studied. The patients will be identified and asked about participation when they come for postoperative control after rectal cancer operation and are planned for the ileostomy reversal after check of the rectal anastomosis. They will be given oral and written information and signed informed consent is required from all patients.
At operation the operation-protocol should be filled in. The operation notes will be written in a blinded way and the original version will be stored on paper until after the study is finished and then added to the patient chart.
At discharge from the surgical ward the patient should be planned for a follow up at the surgical clinic at 30 days postoperatively. The doctor at the follow up visit should be another than the operating surgeon. The patients should then fill in a questionnaire and the surgeon should note the postoperative complications in the 30-days follow up form. At the 30-day follow up the surgeon checks that the one-year follow up after the cancer operation is commissioned. Normally this is a CT thorax and abdomen with contrast. For the study-patients it should be complemented with the question of hernia and the CT scan shall be a CT with straining. The normal 1-year follow up for the cancer will be the follow up for the ileostomy reversal also. That means that in most cases it will take place 6-9 months after the reversal. At this control and at the three years control (after cancer operation) the patient will be given or mailed a questionnaire (the same as the 30-day questionnaire). The follow up by doctor could be done either with a clinical visit or a telephone call according to the routines of the clinic when they follow up their cancer patients. At three years follow up after cancer operation patients will also get the same questionnaire and the CT scan follow up at three years will also be with straining.
- Conditions
- Loop Ileostomy
- Being tested
- Mesh reinforcement, No reinforcement
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mesh reinforcementCombination product
Reinforcement of the abdominal wall with Ultrapro Advanced.
No reinforcementOther
Suturing the abdominal wall without mesh reinforcement
| Study group | Role | What they receive |
|---|---|---|
| Mesh reinforcement | Experimental | Retro muscular mesh at the stoma site. Receives: Combination Product: Mesh reinforcement |
| No reinforcement | Placebo comparator | Standard closure of the abdominal wall Receives: Other: No reinforcement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hernia
Hernia at the site of the stomal closure
Measured: One year
Secondary outcomes (5)
Operation time
Total operation time
Measured: Three hours
Time for closing the stoma site
Time required to close the stoma site
Measured: One hour
Hospital stay
Days to discharge
Measured: Seven days
Postoperative pain
Pain assessed on a Visual analogue scale ranging from 0 to 100, without subscales. 0 corresponds to no pain and 100 the most intense pain sensation imaginable.
Measured: Thirty days
Postoperative complications
Complications, including surgical site infections
Measured: Thirty days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2018
- Study start1 Mar 2018
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Loop IleostomyStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Stockholm South General Hospital
- Responsible party
- Principal investigator, Åsa Hallqvist Everhov, Karolinska Institutet
- Investigators
- Åsa Hallqvist Everhov, MS, PhD, Principal investigator, Stockholm South General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03720262
- Sponsor's protocol ID
- PHaLIR
- Acronym
- PHaLIR
- Status last verified
- Aug 2025
- First submitted
- 24 Oct 2018
- Last updated
- 19 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Eklov K, Bringman S, Lofgren J, Nygren J, Everhov AH. PHaLIR: prevent hernia after loop ileostomy reversal-a study protocol for a randomized controlled multicenter study. Trials. 2023 Sep 8;24(1):575. doi: 10.1186/s13063-023-07430-w.
PubMed 37684648
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevention of Hernia After Loop Ileostomy Reversal
- ClinicalTrials.gov ID
- NCT03720262
- Acronym / sponsor ID
- PHaLIR / PHaLIR
- Conditions
- Loop Ileostomy
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 208 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Stockholm South General Hospital
- Study start
- 1 Mar 2018 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 25 Oct 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery are randomized between retro muscular mesh Ultrapro Advanced or standard treatment without mesh.
Detailed description
A temporary loop ileostomy is widely used when operating rectal cancer. The ostomy is then reversed in a separate operation. Morbidity of stoma reversal is significant, but not clearly defined. One complication in connection with stoma closure is development of hernia at the former stoma site.
A hernia is a weakening of the muscular layers and the connective tissue of the abdominal wall, which may cause pain and discomfort, as well as an inconvenient bulge. A hernia could also cause more serious complication of obstructed or strangulated bowel. According to international studies, the incidence of hernia at the ostomy site varies between 7% and 35%. Many of the studies are heterogenic and some of them include both colostomies and ileostomies. Among studies that focus on reversal of ileotomies the hernia incidence varies between 11-15%. Preliminary results from a retrospective study in Stockholm indicates a frequency of 7,9%.
The best method to avoid hernia after stoma closure is not known. Most commonly surgeons tend to close the fascia in one layer with monofilament suture. In the study mentioned above 91% of the operations were done with one-layer monofilament, mostly PDS. Use of prophylactic mesh in the abdominal wall has been proposed, but there is currently insufficient scientific evidence to recommend it as a routine.
The present study is focused on loop ileostomy closure after rectal cancer. A non-heterogenous group of ostomies will serve as a base to evaluate whether the incidence of hernia may be reduced. If this study detects a decreased frequency of hernia when using prophylactic meshes, it may lead to new recommendations for this patient group.
PHaLIR is a prospective, double-blinded randomized study in which patients planned for stoma reversal after rectal cancer surgery will be randomized to retro muscular mesh Ultrapro Advanced or standard treatment without mesh. Operating time, complications, LOS, pain, infections and postoperative hernia are to be studied. The patients will be identified and asked about participation when they come for postoperative control after rectal cancer operation and are planned for the ileostomy reversal after check of the rectal anastomosis. They will be given oral and written information and signed informed consent is required from all patients.
At operation the operation-protocol should be filled in. The operation notes will be written in a blinded way and the original version will be stored on paper until after the study is finished and then added to the patient chart.
At discharge from the surgical ward the patient should be planned for a follow up at the surgical clinic at 30 days postoperatively. The doctor at the follow up visit should be another than the operating surgeon. The patients should then fill in a questionnaire and the surgeon should note the postoperative complications in the 30-days follow up form. At the 30-day follow up the surgeon checks that the one-year follow up after the cancer operation is commissioned. Normally this is a CT thorax and abdomen with contrast. For the study-patients it should be complemented with the question of hernia and the CT scan shall be a CT with straining. The normal 1-year follow up for the cancer will be the follow up for the ileostomy reversal also. That means that in most cases it will take place 6-9 months after the reversal. At this control and at the three years control (after cancer operation) the patient will be given or mailed a questionnaire (the same as the 30-day questionnaire). The follow up by doctor could be done either with a clinical visit or a telephone call according to the routines of the clinic when they follow up their cancer patients. At three years follow up after cancer operation patients will also get the same questionnaire and the CT scan follow up at three years will also be with straining.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Mesh reinforcement | Experimental | Combination Product: Mesh reinforcementRetro muscular mesh at the stoma site. |
| No reinforcement | Placebo comparator | Other: No reinforcementStandard closure of the abdominal wall |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients operated for low anterior resection for rectal cancer with a diverting loop ileostomy and planned for stoma reversal
Key exclusion criteria (2 listed)
- Language barrier or cognitive disability
- Recurrent cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mesh reinforcementReinforcement of the abdominal wall with Ultrapro Advanced. | Combination product | Mesh reinforcement |
| No reinforcementSuturing the abdominal wall without mesh reinforcement | Other | No reinforcement |
Primary outcome
Hernia
Time frame: One year
Hernia at the site of the stomal closure
5 secondary outcomes
Operation time
Time frame: Three hours
Time for closing the stoma site
Time frame: One hour
Hospital stay
Time frame: Seven days
Postoperative pain
Time frame: Thirty days
Postoperative complications
Time frame: Thirty days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2025.
- Derived from this study: PubMed 37684648Eklov K, Bringman S, Lofgren J, Nygren J, Everhov AH. PHaLIR: prevent hernia after loop ileostomy reversal-a study protocol for a randomized controlled multicenter study. Trials. 2023 Sep 8;24(1):575. doi: 10.1186/s13063-023-07430-w.
- Individual participant dataSharing planned: No
Related trials for Loop Ileostomy
Not yet recruiting
Phasix Mesh Underlay During Loop Ileostomy Closure
Incisional Hernia of Anterior Abdominal Wall
RecruitingObservational study
Implementation of an Efferent Loop Stimulation Protocol Prior to Ileostomy Closure at La Paz University Hospital
Postoperative Ileus, Colorectal Cancer Control and Prevention
Recruiting
Enteral Feeding of Fibre to Improve Microbiota
Bowel Dysfunction, Colon Disease
Active, not recruiting
PRELOOP Trial: Synthetic Versus Biological Mesh for Prevention of Incisional Hernia After Loop-ileostomy Closure
Rectum Cancer
Recruiting
Loop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site?
Rectal Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jonas Nygren, MD, PhD contact
Åsa Hallqvist Everhov, MS, PhD principal investigator
Stockholm South General Hospital
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Mesh reinforcement and No reinforcement in people with Loop Ileostomy, run by Karolinska Institutet at 4 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Åsa Hallqvist Everhov, MD, PhD (+46702264127, asa.hallqvist-everhov@sll.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hernia (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03720262, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2025.